- Category: ICUS Weekly News Monitors
1. American College of Radiology, Sep 1, 2016, ACR CEUS LI-RADS 2016 - The ACR announces the official release of CEUS LI-RADS.
2. International Contrast Ultrasound Society (ICUS), Sep 9, 2016, Contrast Ultrasound Identifies Deadly Liver Cancers (Business Wire)
3. International Contrast Ultrasound Society (ICUS), Sep 8, 2016, CEUS Liver and Kidney Tests Produce Big Savings in Testing Time and Cost (Business Wire)
*To view presentations live-streamed from the 31st Annual Advances in Contrast Ultrasound Bubble Conference held in Chicago, 8/9 September 2016, go to: www.livemedia.com/register/bubble16
American College of Radiology
Sep 1, 2016
ACR CEUS LI-RADS 2016
The ACR announces the official release of CEUS LI-RADS.
ACR CEUS LI-RADS, or CEUS LI-RADS for short, is a standardized system for technique, interpretation, reporting, and data collection for contrast-enhanced ultrasound (CEUS) exams in patients at risk for developing HCC. The system currently includes a lexicon of controlled terminology, schematic illustrations, and a categorization algorithm. A complete illustrative atlas, reporting guidelines, and educational material are in development. CEUS LI-RADS will be updated as experience accrues, as knowledge add technology advance, and in response to user feedback.
ACR CEUS LI-RADS was developed by working group of national and international experts. The group is Chaired by Dr. Yuko Kono, MD, of the University of California, San Diego. Members include radiologists and hepatologists from the United States, Canada, Europe, and Asia. The group was convened in April 2014. Beta versions of the CEUS LI-RADS algorithm were presented at national and international conferences in 2015 and 2016. Feedback was solicited. Based on the feedback and iterative consensus, the working group refined and in 5-21-16 finalized the CEUS LI-RADS algorithm. The algorithm was officially approved by the ACR LI-RADS Steering Committee on 6-24-16 and submitted to the ACR for public release on 6-24-16.
Please click here to view the complete CEUS LI-RADS 2016 Presentation »
International Contrast Ultrasound Society (ICUS)
Sep 9, 2016
Contrast Ultrasound Identifies Deadly Liver Cancers
CHICAGO -- (Business Wire) -- Tiny microbubbles are being used to more effectively identify liver tumors, according to a study described today at the 31st annual Advances in Contrast Ultrasound conference in Chicago.
Patients with hepatocellular carcinoma, the third leading cause of cancer deaths worldwide, were found to benefit from contrast-enhanced ultrasound (CEUS) imaging when MRI imaging was inconclusive, according to Dr. Stephanie Wilson, a professor of medicine at the University of Calgary in Canada and Co-President of the International Contrast Ultrasound Society. She said that inconclusive MRIs occur frequently.
"This is an exciting option because hepatocellular carcinoma is the most common form of liver cancer, and standard imaging with MRI is often an insufficient option for characterizing the tumor," Dr .Wilson said.
CEUS uses liquid suspensions of tiny gas microbubbles to improve the clarity and reliability of an ultrasound image without exposing patients to ionizing radiation. The microbubbles are smaller than red blood cells and, when they are injected into a patient's arm vein, they improve the accuracy of diagnostic ultrasound exams. The microbubbles are expelled from the body within minutes.
David Cosgrove, Emeritus Professor at Imperial and Kings Colleges London, said the findings demonstrate the vast potential benefits of using microbubble ultrasound contrast agents as a safe, convenient and effective diagnostic imaging tool that improves patient care without exposing individuals to ionizing radiation. "CEUS is an excellent modality that can help differentiate benign from malignant tumors," he added.
*View the original presentation delivered by Dr Stephanie Wilson at the 31st Annual Advances in Contrast Ultrasound Bubble Conference by going to: www.livemedia.com/register/bubble16
International Contrast Ultrasound Society (ICUS)
Sep 8, 2016
CEUS Liver and Kidney Tests Produce Big Savings in Testing Time and Cost
CHICAGO -- (Business Wire) - Contrast-enhanced ultrasound (CEUS) can speed up the diagnosis of patients with liver and kidney diseases, reduce the need for more expensive downstream MR and CT imaging, and reduce overall imaging costs, according to a new study described today at the 31st annual Advances in Ultrasound conference in Chicago.
According to Dr. Edward Grant, a professor of medicine at the University of Southern California Keck School of Medicine, patients with liver and kidney masses identified on routine ultrasound scans were examined with CEUS at Los Angeles County General Hospital. He and his colleagues determined that the hospital could anticipate a reduction of 339 CT and 53 MRIs annually by using contrast ultrasound tests first - a potential $132,000 cost reduction each year.
CEUS "is comparable to CT and MRI exams in its capacity to characterize liver and kidney lesions, such as hepatocellular carcinoma and hemangiomas," Dr. Grant said. "But what is remarkable is that CEUS results were usually added to the patient chart the same day, with over 72% done within 24 hours."
By comparison, the mean time to diagnosis and study completion was up to 52 days for CT exams and up to 123 days for an MRI, Dr. Grant added.
The study also found that CEUS reduced the need for CT and MRI follow up exams in the liver and kidney. Dr. Grant noted that "66.7 percent of the CEUS exams were deemed of sufficient quality to not require further evaluation with CT or MRI."
"Ultrasound contrast agents are safe, low cost, and completely radiation-free imaging tools that can improve the clarity and reliability of front-line ultrasound scans of the heart and enhance the ability of routine CEUS scans to characterize tumors in the liver and kidneys. They avoid unnecessary downstream testing, save lives and lower overall health care costs," according to Dr. Steven Feinstein, Co-President of the International Contrast Ultrasound Society (ICUS), who is an expert in cardiac CEUS and professor of medicine at Rush University Medical Center in Chicago.
He noted that previous studies in cardiac patients showed that CEUS could also cut costs and help avoid downstream testing in those populations.
"This is an outstanding example of patient-centered care, since CEUS provided same day diagnoses and avoided lengthy diagnostic delays associated with CT or MRI," according to Dr. Stephanie Wilson, Co-President of ICUS. Dr. Wilson is an expert in abdominal CEUS and a professor of medicine at the University of Calgary in Canada.
"Coupled with the significant cost savings, CEUS offers an enormous improvement in patient management and care." she added.
Three ultrasound contrast agents, Definity (Lantheus Medical Imaging), Optison (GE Healthcare), and Lumason (Bracco Diagnostics) are available in the United States. Definity and Optison are approved by the Food and Drug Administration for cardiac imaging only, while Lumason is approved for both cardiac and liver imaging.
*View the original presentation delivered by Dr Ed Grant at the 31st Annual Advances in Contrast Ultrasound Bubble Conference by going to: www.livemedia.com/register/bubble16